The Effect of Fluphenazine and Thioridazine on In Vivo

Overview

Journal Iran J Parasitol

Publisher Tehran University of Medical Sciences

Specialty Parasitology

Date 2017 Jan 19

PMID 28096857

Citations 4

Authors

Mehrzad Saraei

Yosef Ghaderi

Tahereh Mosavi

Mojtaba Shahnazi

Marjan Nassiri-Asl

Hassan Jahanihashemi

Affiliations

Soon will be listed here.

Abstract

Background: is the most common parasite causing latent cerebral infections in human. It has been shown that some anti-psychotic drugs are able to inhibit the proliferation of the parasite in in vitro study. There is very limited data regarding the inhibitory effect of anti-psychotics on Toxoplasma in in vivo. In this study, we evaluated anti- activity of fluphenazine and thioridazine drugs on in mice.

Methods: Mice were divided into six groups: Control, sesame as vehicle, thioridazine 10 mg/kg, thioridazine 20 mg/kg, fluphenazine 0.06 mg/kg and fluphenazine 0.6 mg/kg. They were inoculated intraperitoneally with brain suspension containing tissue cysts of Tehran strain. Two months after inoculation, the number of cysts in crushed smears of mice brain were counted microscopically and considered as an indicator of anti- activity. This work has conducted in Qazvin, central Iran, 2014.

Results: Our study showed that fluphenazine and thioridazine could not significantly inhibit the brain cystogenesis of in mice. However, the number of brain cysts was less at higher dose compared to lower doses for both drugs.

Conclusion: Further studies need to clear the mechanism of different structure of anti-psychotic drugs on activity of .

Citing Articles

A High-Throughput Amenable Dual Luciferase System for Measuring Bradyzoite Viability after Drug Treatment.

Smith D, Lunghi M, Olafsson E, Hatton O, Di Cristina M, Carruthers V Anal Chem. 2022; 95(2):668-676.

PMID: 36548400 PMC: 9850410. DOI: 10.1021/acs.analchem.2c02174.

Emerging Therapeutic Targets Against : Update on DNA Repair Response Inhibitors and Genotoxic Drugs.

Angel S, Vanagas L, Ruiz D, Cristaldi C, Saldarriaga Cartagena A, Sullivan Jr W Front Cell Infect Microbiol. 2020; 10:289.

PMID: 32656097 PMC: 7325978. DOI: 10.3389/fcimb.2020.00289.

Activities of anti-Toxoplasma drugs and compounds against tissue cysts in the last three decades (1987 to 2017), a systematic review.

Montazeri M, Mehrzadi S, Sharif M, Sarvi S, Shahdin S, Daryani A Parasitol Res. 2018; 117(10):3045-3057.

PMID: 30088074 DOI: 10.1007/s00436-018-6027-z.

A Systematic Review of and Activities of Anti Drugs and Compounds (2006-2016).

Montazeri M, Sharif M, Sarvi S, Mehrzadi S, Ahmadpour E, Daryani A Front Microbiol. 2017; 8:25.

PMID: 28163699 PMC: 5247447. DOI: 10.3389/fmicb.2017.00025.

References

Dickerson F, Stallings C, Boronow J, Origoni A, Yolken R . A double-blind trial of adjunctive azithromycin in individuals with schizophrenia who are seropositive for Toxoplasma gondii. Schizophr Res. 2009; 112(1-3):198-9. DOI: 10.1016/j.schres.2009.05.005. View

Flegr J . Influence of latent Toxoplasma infection on human personality, physiology and morphology: pros and cons of the Toxoplasma-human model in studying the manipulation hypothesis. J Exp Biol. 2012; 216(Pt 1):127-33. DOI: 10.1242/jeb.073635. View

Horacek J, Flegr J, Tintera J, Verebova K, Spaniel F, Novak T . Latent toxoplasmosis reduces gray matter density in schizophrenia but not in controls: voxel-based-morphometry (VBM) study. World J Biol Psychiatry. 2011; 13(7):501-9. DOI: 10.3109/15622975.2011.573809. View

Carroll F, Houghten R . From rapid in vitro screening to rapid in vivo screening in the drug discovery process. Neuropsychopharmacology. 2008; 34(1):251-2. DOI: 10.1038/npp.2008.160. View

Song H, Ahn M, Ryu J, Min D, Joo K, Lee Y . Influence of calcium ion on host cell invasion and intracellular replication by Toxoplasma gondii. Korean J Parasitol. 2004; 42(4):185-93. PMC: 2717384. DOI: 10.3347/kjp.2004.42.4.185. View

Goodwin D, Strobl J, Lindsay D . Evaluation of five antischizophrenic agents against Toxoplasma gondii in human cell cultures. J Parasitol. 2011; 97(1):148-51. DOI: 10.1645/GE-2536.1. View

Alipour A, Shojaee S, Mohebali M, Tehranidoost M, Abdi Masoleh F, Keshavarz H . Toxoplasma infection in schizophrenia patients: a comparative study with control group. Iran J Parasitol. 2012; 6(2):31-7. PMC: 3279881. View

Strobl J, Cassell M, Mitchell S, Reilly C, Lindsay D . Scriptaid and suberoylanilide hydroxamic acid are histone deacetylase inhibitors with potent anti-Toxoplasma gondii activity in vitro. J Parasitol. 2007; 93(3):694-700. DOI: 10.1645/GE-1043R.1. View

Hrda S, Votypka J, Kodym P, Flegr J . Transient nature of Toxoplasma gondii-induced behavioral changes in mice. J Parasitol. 2000; 86(4):657-63. DOI: 10.1645/0022-3395(2000)086[0657:TNOTGI]2.0.CO;2. View

10.

Goodwin D, Strobl J, Mitchell S, Zajac A, Lindsay D . Evaluation of the mood-stabilizing agent valproic acid as a preventative for toxoplasmosis in mice and activity against tissue cysts in mice. J Parasitol. 2008; 94(2):555-7. DOI: 10.1645/GE-1331.1. View

11.

Daryani A, Sarvi S, Aarabi M, Mizani A, Ahmadpour E, Shokri A . Seroprevalence of Toxoplasma gondii in the Iranian general population: a systematic review and meta-analysis. Acta Trop. 2014; 137:185-94. DOI: 10.1016/j.actatropica.2014.05.015. View

12.

Jones J, Kruszon-Moran D, Rivera H, Price C, Wilkins P . Toxoplasma gondii seroprevalence in the United States 2009-2010 and comparison with the past two decades. Am J Trop Med Hyg. 2014; 90(6):1135-9. PMC: 4047742. DOI: 10.4269/ajtmh.14-0013. View

13.

Jones-Brando L, Torrey E, Yolken R . Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophr Res. 2003; 62(3):237-44. DOI: 10.1016/s0920-9964(02)00357-2. View

14.

Pezzella N, Bouchot A, Bonhomme A, Pingret L, Klein C, Burlet H . Involvement of calcium and calmodulin in Toxoplasma gondii tachyzoite invasion. Eur J Cell Biol. 1997; 74(1):92-101. View

15.

McConkey G, Martin H, Bristow G, Webster J . Toxoplasma gondii infection and behaviour - location, location, location?. J Exp Biol. 2012; 216(Pt 1):113-9. PMC: 3515035. DOI: 10.1242/jeb.074153. View

16.

Park M, Kwon Y, Jeong H, Lee H, Hwangbo Y, Yoon H . Association between Intracellular Infectious Agents and Schizophrenia. Clin Psychopharmacol Neurosci. 2013; 10(2):117-23. PMC: 3569146. DOI: 10.9758/cpn.2012.10.2.117. View

17.

Yolken R, Dickerson F, Torrey E . Toxoplasma and schizophrenia. Parasite Immunol. 2009; 31(11):706-15. DOI: 10.1111/j.1365-3024.2009.01131.x. View

18.

Berdoy M, Webster J, Macdonald D . Fatal attraction in rats infected with Toxoplasma gondii. Proc Biol Sci. 2000; 267(1452):1591-4. PMC: 1690701. DOI: 10.1098/rspb.2000.1182. View

19.

Walker E, Kestler L, Bollini A, Hochman K . Schizophrenia: etiology and course. Annu Rev Psychol. 2004; 55:401-30. DOI: 10.1146/annurev.psych.55.090902.141950. View

20.

Webster J, Lamberton P, Donnelly C, Torrey E . Parasites as causative agents of human affective disorders? The impact of anti-psychotic, mood-stabilizer and anti-parasite medication on Toxoplasma gondii's ability to alter host behaviour. Proc Biol Sci. 2006; 273(1589):1023-30. PMC: 1560245. DOI: 10.1098/rspb.2005.3413. View